December 21, 2021
Novavax vaccine get approvals and recommendations
Novavax Monday said that the European Medicines Agency (EMA) has recommended granting a conditional marketing authorization for its ‘ COVID-19 vaccine.
Pharmaceuticals, Biotechnology and Life Sciences
Tag: Novavax
March 31, 2021
GSK to support manufacture of Novavax’ COVID-19 vaccine
GSK has reached an agreement in principle with Novavax and the UK Government Vaccines Taskforce to support manufacturing of up…
May 11, 2020
Novavax gets up to $388M from CEPI for COVID-19 vaccine making
Novavax said Monday that the Coalition for Epidemic Preparedness Innovations (CEPI) will invest up to $384 million of additional funding, on top of $4 million it invested in March, to advance clinical development of NVX-CoV2373, Novavax’ coronavirus vaccine candidate against SARS-CoV-2.
March 24, 2020
Novavax with positive score in Phase 3 of NanoFlu
Novavax published positive top-line results of its pivotal Phase 3 clinical trial of NanoFlu, its recombinant quadrivalent seasonal influenza vaccine candidate with its proprietary Matrix-M adjuvant, in adults aged 65 and older.
January 4, 2019
Novavax’ NanoFlu formulkation identified for the Phase 3 clinical trial and sale
Novavax reported Friday that the Phase 2 clinical trial found all formulations of NanoFlu were well-tolerated and elicited vigorous immune responses to the four strains included in the vaccine.
March 1, 2018
Novavax plans Phase 2 trial of NanoFlu vaccine in third quarter of 2018
NanoFlu vaccine was well tolerated over the three-week trial period, Novavax said Thursday, adding it now expects to begin a…